Brii Biosciences Limited
Research Brii Biosciences Limited (7SS) on Bullrun: market cap EUR 73.56M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7SS
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 73.56M
- Financial periodFY2025
- RevenueEUR 18.61M
- Net income-EUR 222.62M
- Free cash flow-EUR 465.80M
Valuation Snapshot
latest market cap is EUR 73.56M.
About Brii Biosciences Limited
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B;
Frequently asked questions
What is Brii Biosciences Limited's market cap?
Brii Biosciences Limited's market capitalization is EUR 73.56M.
What does Brii Biosciences Limited do?
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate;